2Seventy Bio — Investor Presentation (June 2024)
24 slides from 2Seventy Bio's investor presentation, Jun 11, 2024
Slide 1: Unleash Time: 2seventy bio company presentation May 2024
Unleash Time2seventy bio company presentation May 2024
Slide 2: Cautionary note regarding forward-looking statements
2 Cautionary note regarding forward-looking statements strategies, timelines and expectations with respect to the development and commercialization of Abecma Abecma; the progress and results of our commercialization of Abecma, including our goal of increasing manufacturing capacity and improving the
Slide 3: Unlocking Abecma Value in 2024
Unlocking Abecma Value in 2024 3 Abecma opportunity to see sustainable growth Strong cash and path to profitability Lean, fit-for-purpose structure First-in-class CAR T treatment for 3L+ r/r multiple myeloma $358M total US commercial revenue in 2023; $52M in 1Q24 1 month into the launch of Abecma in
Slide 4: Regeneron asset purchase agreement and strategic realignment
Regeneron asset purchase agreement and strategic realignment Closed April 2024 4 Completed asset purchase agreement with Regeneron: sold oncology and autoimmune research and development programs 2seventy focused exclusively on development and commercialization of Abecma, creating path to financial s
Slide 5: Abecma Poised for a Comeback
Abecma Poised for a Comeback 5 Reset and Return to Growth Prepared to meet demand in 3L+ Educate on competitive efficacy and safety profile with 3L+ label and RWE Educate on treatment sequencing and the importance of bridging Long Term Future Potential approval in NDMM following completion of KarMMa
Slide 6: KarMMa-3 supports the totality of Abecma profile
6 KarMMa-3 supports the totality of Abecma profile in a population of patients with high unmet need Abecma is now available for the treatment of adult patients with relapsed or refractory multiple myeloma earlier in their treatment journey SUPERIOR EFFICACY VS. STANDARD REGIMENS 3x longer mPFS 1 20.
Slide 7: Large global studies show Abecma real-world efficacy consistent with KarMMa
Several large global studies show Abecma efficacy in the real world is consistent or better than the KarMMa study Many RWE patients across all studies would not have met the Safety data similar to KarMMa with no new safety signals; limited Parkinsonism and Guillain-Barre and low non- relapse mortali
Slide 8: KarMMa-3 and KarMMa-9 potential to drive label expansion
KarMMa-3 and planned KarMMa-9 front-line study have the potential to drive label expansion into broad U.S. market opportunity 8 Addressable U.S. Patients on Abecma label over time M ul tip le M ye lo m a Total Addressable U.S. Patient Population: ~21,000 2021 2024 2028+ 0 5,000 10,000 15,000 20,000
Slide 9: Key questions on Abecma in earlier lines
Key questions on Abecma in earlier lines 9 What is the potential profile of Abecma in front line? What did we learn from KarMMa-3 in terms of OS? What does this mean for Abecma in the 3L+ commercial setting? What are you doing to shift the dynamics in the market? KarMMa-2c data demonstrate potential
Slide 10: KarMMa-2c
KarMMa-2c eseventybio
Slide 11: KarMMa-2c: Deepened responses in patients with inadequate response to frontline ASCT
KarMMa-2c: Deepened responses in patients with inadequate response to frontline ASCT (<VGPR) 11 based on IMWG criteria by investigator assessment. D, day; LEN, lenalidomide; M, month. Le na lid om id e m ai nt en an ce N o le na lid om id e m ai nt en an ce DAYS ON STUDY KarMMa-2 cohort 2c CR/sCR VG
Slide 12: KarMMa-2c: deep and durable responses support KarMMa-9 design
KarMMa-2c: deep and durables responses in suboptimal ASCT responders support KarMMa-9 design KarMMa-2c data support conviction in transformative potential of Abecma in front-line setting 12 With a median follow-up of 39.4 months, the ORR in patients treated with Abecma (n=31) was 87.1% (95% CI: 70.2
Slide 13: KarMMa-3
KarMMa-3 eseventybio
Slide 14: KarMMa-3 study design (NCT03651128)
KarMMa-3 study design (NCT03651128) 14 KarMMa-3 updated analysis R 2:1 Key inclusion criteria 2-4 previous regimens (including an IMiD agent, PI, and daratumumab) Refractory to the last regimen Stratification factors Number of previous regimens (2 vs 3 or 4) High-risk cytogenetics (yes vs no/unknown
Slide 15: Heavily Pretreated, Triple Class Exposed Patient Population
Heavily Pretreated, Triple Class Exposed* Patient Population 15 KarMMa-3 updated analysis Characteristic Ide-cel (n = 254) Standard regimens (n = 132) Median (range) age, years Median (range) time from diagnosis to screening, years Previous autologous HSCT 214 (84) 114 (86) R-ISS disease stage I 50
Slide 16: Significant benefit with ide-cel at final PFS analysis
Significant benefit with ide-cel at final PFS analysis (ITT population) 16 KarMMa-3 updated analysis PFS was analyzed in the ITT population of all randomized patients in both arms and included early PFS events occurring between randomization and ide-cel infusion. PFS based on IMWG criteria per IRC.
Slide 17: Statistically significant, deep and durable responses with ide-cel
Ide-cel Standard regimens 100 80 60 40 20 0 10 26 18 11 41 5 Statistically significant, deep and durable responses with ide- cel KarMMa-3 updated analysis Per IMWG criteria. Individual responses may not sum to ORR due to rounding. aOR is for ORR, calculated based on the observed response rate with t
Slide 18: OS analysis confounded by substantial crossover
Information fraction for OS was 74% (n = 164/222 required events). a bStratified HR is based on the univariate Cox proportional hazards model. CI is 2-sided and calculated by bootstrap method; cTwo-stage Weibull model without recensoring (prespecified analysis). NR, not reached. OS analysis confound
Slide 19: Patients who never received ide-cel drive imbalance in early OS events
Patients who never received ide-cel drive imbalance in early OS events 19 a bIncluded del17p13 (reflective of del[17p]), t(14;16), or t(4;14); cDetermined by the higher randomization, n (%) Ide-cel (n = 254) Standard regimens (n = 132) Patients who died 30 (12) 9 (7) Did not receive study treatment
Slide 20: Suboptimal bridging therapy
Suboptimal bridging therapy 20 Cumulative dose during bridging therapy for the ide-cel arm and cycles 1 and 2 for the standard regimens arm was defined as the sum of all doses taken in mg. Dose intensity was defined as the cumulative dose divided by total days. aFor patients in the ide-cel arm, brid
Slide 21: Trend of OS benefit with ide-cel among treated patients
Trend of OS benefit with ide-cel among treated patients 21 KarMMa-3 updated analysis a bStratified HR based on the univariate Cox proportional hazards model. CI is two-sided. O S (% ) HR 0.83 (95% CI, 0.58 1.18) Median OSa Hazard ratiob NR NR Ide-cel Standard regimens 0 3 6 9 12 15 18 21 24 27 30 33
Slide 22: KarMMa-3 Data Supports the Potential of Abecma in Earlier Lines
KarMMa-3 Data Supports the Potential of Abecma in Earlier Lines 22 KarMMa-3 demonstrates a significantly longer and clinically meaningful improvement of PFS with ide-cel versus standard regimens in patients with early line relapse and triple-class exposed* (TCExp) RRMM across all subgroups1 51% redu
Slide 23: Abecma Data at ASH Reinforce Potential in Earlier Lines
Abecma Data at ASH Reinforce Potential in Earlier Lines and Differentiated Safety Profile Encouraging phase II data in patients with suboptimal response to ASCT ORR: 87.1%; CRR: 77.4%, at 36mts PFS was 76.8% None of 8 patients with lenalidomide maintenance after ide-cel progressed These data are hig
Slide 24: THANK YOU
THANK YOU eseventybio